Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $60.00 to $142.00. On average, they expect the company's stock price to reach $112.09 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE shares have decreased by 50.8% and is now trading at $41.41.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings results on Thursday, July, 28th. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.54. The biopharmaceutical company earned $89.34 million during the quarter, compared to analysts' expectations of $87.33 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 60.76% and a negative net margin of 151.34%. The firm's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.45) earnings per share.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $41.41.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.90 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($7.32) on an earnings per share basis.

The company employs 1,119 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.